Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Alcaftadine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Alcaftadine | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Alcaftadine | hsa00071 | Fatty acid degradation | 3.50E-02 | 4 | O75521, P00325, P11766, P33121 | ECI2, ADH1B, ADH5, ACSL1 | More | | Alcaftadine | hsa00190 | Oxidative phosphorylation | 5.12E-04 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Alcaftadine | hsa00220 | Arginine biosynthesis | 3.83E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | | Alcaftadine | hsa00310 | Lysine degradation | 4.14E-02 | 1 | Q02809 | PLOD1 | More | | Alcaftadine | hsa00500 | Starch and sucrose metabolism | 5.14E-04 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Alcaftadine | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | Alcaftadine | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.11E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Alcaftadine | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Alcaftadine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Alcaftadine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Alcaftadine | hsa00603 | Glycosphingolipid biosynthesis - globo and isoglobo series | 8.72E-03 | 2 | P06865, O75752 | HEXA, B3GALNT1 | More | | Alcaftadine | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.46E-02 | 2 | P06865, Q9H4F1 | HEXA, ST6GALNAC4 | More | | Alcaftadine | hsa00730 | Thiamine metabolism | 3.03E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Alcaftadine | hsa00770 | Pantothenate and CoA biosynthesis | 2.26E-04 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | Alcaftadine | hsa00830 | Retinol metabolism | 2.27E-03 | 5 | P00325, P11766, P00352, Q9BPW9, O75911 | ADH1B, ADH5, ALDH1A1, DHRS9, DHRS3 | More | | Alcaftadine | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.02E-05 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Alcaftadine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Alcaftadine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Alcaftadine | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Alcaftadine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Alcaftadine | hsa01210 | 2-Oxocarboxylic acid metabolism | 1.40E-02 | 1 | P50213 | IDH3A | More | | Alcaftadine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Alcaftadine | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa01523 | Antifolate resistance | 1.43E-03 | 2 | Q92820, P04818 | GGH, TYMS | More | | Alcaftadine | hsa01524 | Platinum drug resistance | 4.78E-02 | 1 | P31751 | AKT2 | More | | Alcaftadine | hsa02010 | ABC transporters | 2.17E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | | Alcaftadine | hsa03013 | RNA transport | 4.09E-02 | 9 | P52298, Q09161, O14893, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, NCBP1, GEMIN2, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | | Alcaftadine | hsa03020 | RNA polymerase | 4.40E-02 | 2 | P24928, P62487 | POLR2A, POLR2G | More | | Alcaftadine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Alcaftadine | hsa03040 | Spliceosome | 1.28E-05 | 13 | O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | Alcaftadine | hsa03320 | PPAR signaling pathway | 4.33E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | | Alcaftadine | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Alcaftadine | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa04012 | ErbB signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa04014 | Ras signaling pathway | 1.71E-03 | 11 | P04049, P31751, P42338, P20827, P49767, Q13009, Q7LDG7, P0DP23, P63218, P50151, P19174 | RAF1, AKT2, PIK3CB, EFNA1, VEGFC, TIAM1, RASGRP2, CALM1, GNG5, GNG10, PLCG1 | More | | Alcaftadine | hsa04015 | Rap1 signaling pathway | 7.70E-04 | 11 | P04049, P20827, P49767, Q96FS4, P11215, Q13009, Q7LDG7, P42338, P31751, P0DP23, P19174 | RAF1, EFNA1, VEGFC, SIPA1, ITGAM, TIAM1, RASGRP2, PIK3CB, AKT2, CALM1, PLCG1 | More | | Alcaftadine | hsa04022 | cGMP-PKG signaling pathway | 2.83E-04 | 7 | P04049, P18848, Q8WYR1, P31751, P05141, P0DP24, P0DP23 | RAF1, ATF4, PIK3R5, AKT2, SLC25A5, CALM2, CALM1 | More | | Alcaftadine | hsa04024 | cAMP signaling pathway | 1.30E-04 | 3 | P31751, P0DP23, P04049 | AKT2, CALM1, RAF1 | More | | Alcaftadine | hsa04060 | Cytokine-cytokine receptor interaction | 5.34E-03 | 11 | P14784, P27930, P14778, P26842, Q06643, Q13651, P25024, Q9UBD3, P47992, P09341, P01730 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, CXCR1, XCL2, XCL1, CXCL1, CD4 | More | | Alcaftadine | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.32E-02 | 6 | P09341, P25024, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCR1, XCL1, XCL2, IL10RA, IL2RB | More | | Alcaftadine | hsa04062 | Chemokine signaling pathway | 1.76E-06 | 19 | P25024, P25025, P09341, P47992, Q9UBD3, P09769, P07948, P42338, P19174, P63218, P50151, P43250, P49407, Q08881, Q7LDG7, Q13009, P04049, P49841, Q8WYR1 | CXCR1, CXCR2, CXCL1, XCL1, XCL2, FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, ARRB1, ITK, RASGRP2, TIAM1, RAF1, GSK3B, PIK3R5 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06239 | LCK | Tyrosine-protein kinase Lck | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | -0.779 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.929 | P06239 | LCK | Tyrosine-protein kinase Lck | P09341 | CXCL1 | Growth-regulated alpha protein | -0.805 | P06239 | LCK | Tyrosine-protein kinase Lck | P47992 | XCL1 | Lymphotactin | 0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P47992 | XCL1 | Lymphotactin | -0.706 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | 0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | -0.706 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P09769 | FGR | Tyrosine-protein kinase Fgr | 0.796 | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.707 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.971 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | P06239 | LCK | Tyrosine-protein kinase Lck | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.728 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.727 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | P06239 | LCK | Tyrosine-protein kinase Lck | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.71 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | P06239 | LCK | Tyrosine-protein kinase Lck | P43250 | GRK6 | G protein-coupled receptor kinase 6 | -0.702 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43250 | GRK6 | G protein-coupled receptor kinase 6 | 0.818 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49407 | ARRB1 | Beta-arrestin-1 | -0.721 | P06239 | LCK | Tyrosine-protein kinase Lck | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.774 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13009 | TIAM1 | Rho guanine nucleotide exchange factor TIAM1 | 0.706 | P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q8WYR1 | PIK3R5 | Phosphoinositide 3-kinase regulatory subunit 5 | 0.752 |
| Alcaftadine | hsa04064 | NF-kappa B signaling pathway | 4.37E-08 | 20 | P10415, Q13489, P25963, P51617, O00463, P14778, P01584, P01375, Q04759, Q9UDY8, Q13077, Q16548, P07948, P06239, Q8WV28, Q13315, P24522, P09341, Q06643, Q9NQC7 | BCL2, BIRC3, NFKBIA, IRAK1, TRAF5, IL1R1, IL1B, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, LYN, LCK, BLNK, ATM, GADD45A, CXCL1, LTB, CYLD | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P08246 | ELA2 | Neutrophil elastase | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.942 | P08246 | ELA2 | Neutrophil elastase | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.716 | P08246 | ELA2 | Neutrophil elastase | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.701 | P08246 | ELA2 | Neutrophil elastase | P51617 | IRAK1 | Interleukin-1 receptor-associated kinase 1 | -0.734 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.932 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P06239 | LCK | Tyrosine-protein kinase Lck | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.718 | P08246 | ELA2 | Neutrophil elastase | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.814 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.766 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01584 | IL1B | Interleukin-1 beta | 0.807 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | P08246 | ELA2 | Neutrophil elastase | P01375 | TNF | Tumor necrosis factor | 0.751 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | P08246 | ELA2 | Neutrophil elastase | Q04759 | PRKCQ | Protein kinase C theta type | -0.748 | P08246 | ELA2 | Neutrophil elastase | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | -0.896 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.796 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.73 | P08246 | ELA2 | Neutrophil elastase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.725 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.958 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.875 | P08246 | ELA2 | Neutrophil elastase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.766 | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q8WV28 | BLNK | B-cell linker protein | -0.704 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q8WV28 | BLNK | B-cell linker protein | -0.816 | P08246 | ELA2 | Neutrophil elastase | Q13315 | ATM | Serine-protein kinase ATM | -0.742 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.819 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.796 | P06239 | LCK | Tyrosine-protein kinase Lck | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.724 | P08246 | ELA2 | Neutrophil elastase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.7 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09341 | CXCL1 | Growth-regulated alpha protein | 0.788 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.7 | P06239 | LCK | Tyrosine-protein kinase Lck | P09341 | CXCL1 | Growth-regulated alpha protein | -0.805 | P06239 | LCK | Tyrosine-protein kinase Lck | Q06643 | LTB | Lymphotoxin-beta | 0.846 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9NQC7 | CYLD | Ubiquitin carboxyl-terminal hydrolase CYLD | 0.799 |
| Alcaftadine | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa04071 | Sphingolipid signaling pathway | 1.54E-04 | 8 | P04049, P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, P10415 | RAF1, PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2 | More | | Alcaftadine | hsa04072 | Phospholipase D signaling pathway | 2.82E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa04080 | Neuroactive ligand-receptor interaction | 1.02E-03 | 9 | P08311, P28472, Q15722, P21453, Q9H228, O00398, P21462, P21730, P07550 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, FPR1, C5AR1, ADRB2 | More | | Alcaftadine | hsa04110 | Cell cycle | 1.97E-05 | 7 | P06493, O60566, O75293, P30304, P33981, P42773, P01106 | CDK1, BUB1B, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | | Alcaftadine | hsa04114 | Oocyte meiosis | 4.19E-04 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Alcaftadine | hsa04115 | p53 signaling pathway | 3.57E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | Alcaftadine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Alcaftadine | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa04145 | Phagosome | 1.98E-02 | 8 | Q15080, P14598, Q13509, Q13488, P05164, O60603, P35443, P13765 | NCF4, NCF1, TUBB3, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | | Alcaftadine | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa04151 | PI3K-Akt signaling pathway | 1.67E-03 | 18 | P62753, P42338, P43657, O43521, P27348, P20827, P49767, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, P18848, O00141, Q6ZUJ8, P30281 | RPS6, PIK3CB, P2RY5, BCL2L11, YWHAQ, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, ATF4, SGK, PIK3AP1, CCND3 | More | | Alcaftadine | hsa04210 | Apoptosis | 3.11E-04 | 13 | Q13315, P10415, Q13489, P25963, P01375, O75460, P24522, Q16548, Q13077, O43521, P18848, Q14643, P04049 | ATM, BCL2, BIRC3, NFKBIA, TNF, ERN1, GADD45A, BCL2A1, TRAF1, BCL2L11, ATF4, ITPR1, RAF1 | More | | Alcaftadine | hsa04217 | Necroptosis | 4.76E-06 | 17 | P01375, P01568, P48023, Q13489, P42224, Q14765, P08238, P15104, P05141, P01584, P0C0S5, Q6FI13, Q99878, Q93077, Q9H444, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, HSP90AB1, GLUL, SLC25A5, IL1B, H2AFZ, H2AC18; H2AC19, H2AC14, HIST1H2AC, CHMP4B, CHMP2A, PPID | More | | Alcaftadine | hsa04218 | Cellular senescence | 3.00E-04 | 7 | P01106, P31751, P04049, O75293, P30304, P06493, P0DP23 | MYC, AKT2, RAF1, GADD45B, CDC25A, CDK1, CALM1 | More | | Alcaftadine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.83E-03 | 6 | P07550, P22694, P31751, P18848, Q13362, P0DP23 | ADRB2, PRKACB, AKT2, ATF4, PPP2R5C, CALM1 | More | | Alcaftadine | hsa04270 | Vascular smooth muscle contraction | 2.32E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa04360 | Axon guidance | 1.51E-02 | 7 | P16333, P20827, O95631, P42338, P07332, P04049, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, RAF1, PLCG1 | More | | Alcaftadine | hsa04370 | VEGF signaling pathway | 1.94E-06 | 5 | P16298, P31751, Q05397, Q02750, P04049 | PPP3CB, AKT2, PTK2, MAP2K1, RAF1 | More | | Alcaftadine | hsa04371 | Apelin signaling pathway | 3.31E-04 | 10 | P63218, P50151, Q8WYR1, P31751, P04049, Q14814, Q14344, Q13485, P84022, P0DP23 | GNG5, GNG10, PIK3R5, AKT2, RAF1, MEF2D, GNA13, SMAD4, SMAD3, CALM1 | More | | Alcaftadine | hsa04380 | Osteoclast differentiation | 1.35E-04 | 13 | Q9NQC7, Q9UQC2, Q16539, P23458, P06239, P31751, P01584, P14778, O75015, Q8WV28, P01375, Q15080, P78324 | CYLD, GAB2, MAPK14, JAK1, LCK, AKT2, IL1B, IL1R1, FCGR3B, BLNK, TNF, NCF4, SIRPA | More | | Alcaftadine | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Alcaftadine | hsa04540 | Gap junction | 1.33E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.58E-03 | 3 | P04628, P40189, P04049 | WNT1, IL6ST, RAF1 | More | | Alcaftadine | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | | Alcaftadine | hsa04612 | Antigen processing and presentation | 9.02E-05 | 8 | P13765, P01730, Q14953, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, CD4, KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Alcaftadine | hsa04613 | Neutrophil extracellular trap formation | 9.62E-07 | 25 | P17252, P04049, O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P04908, P0C0S5, Q6FI13, Q93077, P62807, O60814, P68431, P14598, Q15080, P20160, P08311, P49913, O75015, P21730, P21462, O43315, Q16539 | PRKCA, RAF1, TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AC4; H2AC8, H2AFZ, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, AZU1, CTSG, CAMP, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Alcaftadine | hsa04614 | Renin-angiotensin system | 2.74E-02 | 3 | P15144, P08311, O75787 | ANPEP, CTSG, ATP6AP2 | More | | Alcaftadine | hsa04620 | Toll-like receptor signaling pathway | 4.78E-02 | 1 | P31751 | AKT2 | More | | Alcaftadine | hsa04621 | NOD-like receptor signaling pathway | 3.10E-03 | 11 | Q14643, P25963, Q13489, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P49913, P12838 | ITPR1, NFKBIA, BIRC3, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CAMP, DEFA4 | More | | Alcaftadine | hsa04622 | RIG-I-like receptor signaling pathway | 1.81E-02 | 1 | Q9NQC7 | CYLD | More | | Alcaftadine | hsa04623 | Cytosolic DNA-sensing pathway | 3.15E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Alcaftadine | hsa04625 | C-type lectin receptor signaling pathway | 3.02E-05 | 12 | Q9ULY5, P04049, P01584, Q9NQC7, P20749, Q14643, P01375, Q13191, P31751, P0DP24, P0DP23, Q16539 | CLEC4E, RAF1, IL1B, CYLD, BCL3, ITPR1, TNF, CBLB, AKT2, CALM2, CALM1, MAPK14 | More | | Alcaftadine | hsa04630 | JAK-STAT signaling pathway | 1.01E-04 | 4 | O75925, P40189, Q06124, P04049 | PIAS1, IL6ST, PTPN11, RAF1 | More | | Alcaftadine | hsa04640 | Hematopoietic cell lineage | 4.50E-06 | 16 | P13612, P21926, P14778, P27930, P15144, P11836, P25063, P07766, P09693, P01732, P01730, P06127, P09564, P13765, P01375, P01584 | ITGA4, CD9, IL1R1, IL1R2, ANPEP, MS4A1, CD24, CD3E, CD3G, CD8A, CD4, CD5, CD7, HLA-DOB, TNF, IL1B | More | | Alcaftadine | hsa04650 | Natural killer cell mediated cytotoxicity | 2.33E-10 | 16 | P16298, P50591, P01375, P78314, P06239, O60880, P20963, Q02750, P04049, Q13241, P26718, O14931, O75015, P26717, Q14953, P26715 | PPP3CB, TNFSF10, TNF, SH3BP2, LCK, SH2D1A, CD247, MAP2K1, RAF1, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q6PCB7 | SLC27A1 | Long-chain fatty acid transport protein 1 | P16298 | PPP3CB | Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform | 0.774 | Q6PCB7 | SLC27A1 | Long-chain fatty acid transport protein 1 | P50591 | TNFSF10 | Tumor necrosis factor ligand superfamily member 10 | 0.9 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.761 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.823 | P06239 | LCK | Tyrosine-protein kinase Lck | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.906 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | Q6PCB7 | SLC27A1 | Long-chain fatty acid transport protein 1 | Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 0.799 | P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | 1 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.82 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.91 | P06239 | LCK | Tyrosine-protein kinase Lck | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.886 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.732 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.92 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.846 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.846 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 |
| Alcaftadine | hsa04657 | IL-17 signaling pathway | 2.63E-04 | 9 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375, P01584 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF, IL1B | More | | Alcaftadine | hsa04658 | Th1 and Th2 cell differentiation | 3.56E-07 | 14 | Q04759, P07766, P20963, P09693, Q16539, P01730, P06239, Q14765, P23771, Q9UL17, P14784, P13765, P23458, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, CD4, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, JAK1, RUNX3 | More | | Alcaftadine | hsa04659 | Th17 cell differentiation | 1.83E-07 | 18 | Q04759, Q16539, P19174, P01730, P06239, P14784, P13765, P14778, Q9UL17, P23771, P84022, Q13485, P01584, P08238, P07766, P09693, P20963, P23458 | PRKCQ, MAPK14, PLCG1, CD4, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, SMAD3, SMAD4, IL1B, HSP90AB1, CD3E, CD3G, CD247, JAK1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.785 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.766 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.764 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.872 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.763 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01584 | IL1B | Interleukin-1 beta | 0.807 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.838 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.835 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.757 |
| Alcaftadine | hsa04660 | T cell receptor signaling pathway | 1.22E-07 | 17 | P01375, P25963, Q9UDY8, Q04759, P10747, O95267, Q08881, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, P04049, Q16539, P49841 | TNF, NFKBIA, MALT1, PRKCQ, CD28, RASGRP1, ITK, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, RAF1, MAPK14, GSK3B | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | P08246 | ELA2 | Neutrophil elastase | P01375 | TNF | Tumor necrosis factor | 0.751 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P08246 | ELA2 | Neutrophil elastase | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.701 | P08246 | ELA2 | Neutrophil elastase | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | -0.896 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | P08246 | ELA2 | Neutrophil elastase | Q04759 | PRKCQ | Protein kinase C theta type | -0.748 | P08246 | ELA2 | Neutrophil elastase | P10747 | CD28 | T-cell-specific surface glycoprotein CD28 | -0.854 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.852 | P08246 | ELA2 | Neutrophil elastase | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.724 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.866 | P06239 | LCK | Tyrosine-protein kinase Lck | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.774 | P08246 | ELA2 | Neutrophil elastase | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.782 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.835 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.781 | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.803 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.734 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | 1 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.812 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 |
| Alcaftadine | hsa04662 | B cell receptor signaling pathway | 4.90E-04 | 7 | P31751, P42338, P60033, P07948, P21854, Q8N149, P04049 | AKT2, PIK3CB, CD81, LYN, CD72, LILRA2, RAF1 | More | | Alcaftadine | hsa04664 | Fc epsilon RI signaling pathway | 1.45E-03 | 6 | P31751, P42338, P07948, P19174, P04049, P09917 | AKT2, PIK3CB, LYN, PLCG1, RAF1, ALOX5 | More | | Alcaftadine | hsa04666 | Fc gamma R-mediated phagocytosis | 2.32E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa04668 | TNF signaling pathway | 2.79E-04 | 11 | P01375, O00463, Q13489, P25963, P18848, P19875, P01584, P20749, Q13077, P14780, P20333 | TNF, TRAF5, BIRC3, NFKBIA, ATF4, CXCL2, IL1B, BCL3, TRAF1, MMP9, TNFRSF1B | More | | Alcaftadine | hsa04670 | Leukocyte transendothelial migration | 4.20E-02 | 7 | P14780, Q96A32, P17252, P14598, Q15080, Q08881, P42681 | MMP9, MYLPF, PRKCA, NCF1, NCF4, ITK, TXK | More | | Alcaftadine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Alcaftadine | hsa04720 | Long-term potentiation | 4.88E-03 | 4 | P16298, P51812, Q02750, P04049 | PPP3CB, RPS6KA3, MAP2K1, RAF1 | More | | Alcaftadine | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | Alcaftadine | hsa04722 | Neurotrophin signaling pathway | 2.01E-04 | 6 | P31751, P04049, P49841, O43524, P48023, P0DP23 | AKT2, RAF1, GSK3B, FOXO3, FASLG, CALM1 | More | | Alcaftadine | hsa04726 | Serotonergic synapse | 1.33E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa04728 | Dopaminergic synapse | 3.02E-03 | 8 | P14416, P63218, P50151, P31751, P49841, Q16539, P49407, P0DP23 | DRD2, GNG5, GNG10, AKT2, GSK3B, MAPK14, ARRB1, CALM1 | More | | Alcaftadine | hsa04730 | Long-term depression | 1.16E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa04740 | Olfactory transduction | 9.46E-04 | 2 | Q9H255, P0DP23 | OR51E2, CALM1 | More | | Alcaftadine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Alcaftadine | hsa04744 | Phototransduction | 1.81E-02 | 1 | P0DP23 | CALM1 | More | | Alcaftadine | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.17E-02 | 8 | P14778, P01584, P51828, P22694, Q16539, Q14643, Q04759, P0DP24 | IL1R1, IL1B, ADCY7, PRKACB, MAPK14, ITPR1, PRKCQ, CALM2 | More | | Alcaftadine | hsa04810 | Regulation of actin cytoskeleton | 3.81E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa04910 | Insulin signaling pathway | 2.40E-05 | 3 | P0DP23, P04049, P31751 | CALM1, RAF1, AKT2 | More | | Alcaftadine | hsa04912 | GnRH signaling pathway | 2.74E-02 | 7 | P51828, Q16539, Q9Y6R4, Q14643, P0DP24, P22694, P04049 | ADCY7, MAPK14, MAP3K4, ITPR1, CALM2, PRKACB, RAF1 | More | | Alcaftadine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Alcaftadine | hsa04914 | Progesterone-mediated oocyte maturation | 2.23E-04 | 5 | Q17RY0, Q9Y6D9, P51812, Q02750, P04049 | CPEB4, MAD1L1, RPS6KA3, MAP2K1, RAF1 | More | | Alcaftadine | hsa04915 | Estrogen signaling pathway | 2.42E-04 | 3 | P04049, P31751, P0DP23 | RAF1, AKT2, CALM1 | More | | Alcaftadine | hsa04916 | Melanogenesis | 1.47E-03 | 2 | P0DP23, P04049 | CALM1, RAF1 | More | | Alcaftadine | hsa04917 | Prolactin signaling pathway | 3.49E-04 | 2 | P31751, P04049 | AKT2, RAF1 | More | | Alcaftadine | hsa04919 | Thyroid hormone signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa04920 | Adipocytokine signaling pathway | 6.24E-04 | 7 | P25963, Q06124, P33121, Q9Y478, Q04759, P31751, P01375 | NFKBIA, PTPN11, ACSL1, PRKAB1, PRKCQ, AKT2, TNF | More | | Alcaftadine | hsa04921 | Oxytocin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa04922 | Glucagon signaling pathway | 1.79E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Alcaftadine | hsa04923 | Regulation of lipolysis in adipocytes | 3.01E-02 | 1 | P31751 | AKT2 | More | | Alcaftadine | hsa04924 | Renin secretion | 6.02E-03 | 3 | P22694, P07550, P0DP23 | PRKACB, ADRB2, CALM1 | More | | Alcaftadine | hsa04926 | Relaxin signaling pathway | 6.24E-03 | 5 | P18848, P22694, P14780, P04049, P30679 | ATF4, PRKACB, MMP9, RAF1, GNA15 | More | | Alcaftadine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Alcaftadine | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.99E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa04929 | GnRH secretion | 1.87E-04 | 2 | P31751, P04049 | AKT2, RAF1 | More | | Alcaftadine | hsa04931 | Insulin resistance | 1.48E-02 | 2 | Q06124, Q9Y478 | PTPN11, PRKAB1 | More | | Alcaftadine | hsa04932 | Non-alcoholic fatty liver disease | 1.52E-05 | 10 | P01375, P49841, O43521, P18848, P48023, O75460, P01584, P13073, Q16718, O14521 | TNF, GSK3B, BCL2L11, ATF4, FASLG, ERN1, IL1B, COX4I1, NDUFA5, SDHD | More | | Alcaftadine | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.21E-02 | 5 | P84022, Q13485, P42338, P49767, P19174 | SMAD3, SMAD4, PIK3CB, VEGFC, PLCG1 | More | | Alcaftadine | hsa04935 | Growth hormone synthesis, secretion and action | 2.16E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Alcaftadine | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | Alcaftadine | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | | Alcaftadine | hsa04970 | Salivary secretion | 6.99E-04 | 6 | P07550, P22694, Q14643, P17252, P0DP23, P49913 | ADRB2, PRKACB, ITPR1, PRKCA, CALM1, CAMP | More | | Alcaftadine | hsa04971 | Gastric acid secretion | 4.78E-02 | 1 | P0DP23 | CALM1 | More | | Alcaftadine | hsa04973 | Carbohydrate digestion and absorption | 2.41E-02 | 1 | P31751 | AKT2 | More | | Alcaftadine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | Alcaftadine | hsa05010 | Alzheimer disease | 8.89E-04 | 9 | P13073, Q00535, O75460, P0DP24, P0DP23, P01584, P18848, P31751, P05141 | COX4I1, CDK5, ERN1, CALM2, CALM1, IL1B, ATF4, AKT2, SLC25A5 | More | | Alcaftadine | hsa05012 | Parkinson disease | 3.89E-02 | 5 | P13073, P05141, O75460, P18848, P0DP24 | COX4I1, SLC25A5, ERN1, ATF4, CALM2 | More | | Alcaftadine | hsa05016 | Huntington disease | 4.87E-02 | 5 | P13073, P24928, P62487, P05141, O75460 | COX4I1, POLR2A, POLR2G, SLC25A5, ERN1 | More | | Alcaftadine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | Alcaftadine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.12E-04 | 15 | P49841, Q16718, O14521, P13073, O75460, P18848, Q13561, P05141, P20333, Q16539, Q00535, P01584, Q08752, P0DP24, P0DP23 | GSK3B, NDUFA5, SDHD, COX4I1, ERN1, ATF4, DCTN2, SLC25A5, TNFRSF1B, MAPK14, CDK5, IL1B, PPID, CALM2, CALM1 | More | | Alcaftadine | hsa05030 | Cocaine addiction | 4.19E-02 | 1 | Q00535 | CDK5 | More | | Alcaftadine | hsa05031 | Amphetamine addiction | 6.98E-03 | 4 | P0DP23, P22694, P18848, Q13547 | CALM1, PRKACB, ATF4, HDAC1 | More | | Alcaftadine | hsa05034 | Alcoholism | 2.78E-04 | 5 | P04049, Q93077, P62807, O60814, P68431 | RAF1, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Alcaftadine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.85E-03 | 5 | Q16539, P09341, P25024, P25025, P07948 | MAPK14, CXCL1, CXCR1, CXCR2, LYN | More | | Alcaftadine | hsa05131 | Shigellosis | 3.34E-02 | 11 | P01375, P25963, O00463, Q04759, Q9UDY8, Q9H1Y0, Q14643, Q12778, Q13315, P10415, Q96A32 | TNF, NFKBIA, TRAF5, PRKCQ, MALT1, ATG5, ITPR1, FOXO1, ATM, BCL2, MYLPF | More | | Alcaftadine | hsa05132 | Salmonella infection | 1.81E-02 | 12 | P51617, P25963, P01375, P04049, Q9UJU2, Q13489, P10415, Q96A32, O60603, Q9BQS8, Q13561, Q13509 | IRAK1, NFKBIA, TNF, RAF1, LEF1, BIRC3, BCL2, MYLPF, TLR2, FYCO1, DCTN2, TUBB3 | More | | Alcaftadine | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | | Alcaftadine | hsa05135 | Yersinia infection | 6.38E-03 | 9 | Q05397, P51812, P13612, P06239, Q16539, Q02750, P01375, P49841, Q96JJ3 | PTK2, RPS6KA3, ITGA4, LCK, MAPK14, MAP2K1, TNF, GSK3B, ELMO2 | More | | Alcaftadine | hsa05140 | Leishmaniasis | 4.73E-06 | 15 | P13612, O75015, P14598, P23458, P42224, P13765, O60603, P25963, P01375, P01584, P29350, P49006, Q16539, P51617, Q15080 | ITGA4, FCGR3B, NCF1, JAK1, STAT1, HLA-DOB, TLR2, NFKBIA, TNF, IL1B, PTPN6, MARCKSL1, MAPK14, IRAK1, NCF4 | More | | Alcaftadine | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | Alcaftadine | hsa05144 | Malaria | 1.50E-05 | 8 | P60033, P69905, P68871, O60603, P01375, P35443, P01584, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, IL1B, KLRK1 | More | | Alcaftadine | hsa05145 | Toxoplasmosis | 3.07E-02 | 7 | P51617, P25963, P01375, P10415, Q13489, P13765, O60603 | IRAK1, NFKBIA, TNF, BCL2, BIRC3, HLA-DOB, TLR2 | More | | Alcaftadine | hsa05146 | Amoebiasis | 2.47E-05 | 12 | P01584, P09341, P19875, P14778, P27930, P01375, O60603, P05089, P30679, P22694, P12814, P08311 | IL1B, CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | Alcaftadine | hsa05152 | Tuberculosis | 3.61E-03 | 12 | P04049, Q13488, P0DP23, P48382, O60603, P01375, P31751, P10415, P13765, P49913, Q9UDY8, P51617 | RAF1, TCIRG1, CALM1, RFX5, TLR2, TNF, AKT2, BCL2, HLA-DOB, CAMP, MALT1, IRAK1 | More | | Alcaftadine | hsa05160 | Hepatitis C | 1.40E-03 | 5 | P60033, P04049, P49841, P01375, P48023 | CD81, RAF1, GSK3B, TNF, FASLG | More | | Alcaftadine | hsa05161 | Hepatitis B | 4.82E-03 | 9 | P17252, P04049, P14780, P25963, P01375, P10415, P51617, O60603, Q14765 | PRKCA, RAF1, MMP9, NFKBIA, TNF, BCL2, IRAK1, TLR2, STAT4 | More | | Alcaftadine | hsa05163 | Human cytomegalovirus infection | 1.14E-03 | 13 | P31751, P04049, P01375, P63218, P50151, Q14643, P0DP23, P49841, P14778, P25025, Q16539, P04637, O00463 | AKT2, RAF1, TNF, GNG5, GNG10, ITPR1, CALM1, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5 | More | | Alcaftadine | hsa05164 | Influenza A | 3.65E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 5.30E-04 | 7 | P31751, P62879, P16298, P04049, Q02750, P0DP23, P0CG47 | AKT2, GNB2, PPP3CB, RAF1, MAP2K1, CALM1, UBB | More | | Alcaftadine | hsa05168 | Herpes simplex virus 1 infection | 3.38E-03 | 12 | P25963, P01568, Q05823, P42224, Q07955, Q13243, Q13489, Q13398, Q9HCX3, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS5, BIRC3, ZNF211, ZNF304, ZNF140, ZNF189, ZNF212 | More | | Alcaftadine | hsa05169 | Epstein-Barr virus infection | 4.84E-03 | 10 | P13765, P01106, Q13547, O00463, P07948, Q13761, P24522, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TRAF5, LYN, RUNX3, GADD45A, CD3E, CD3G, CD247 | More | | Alcaftadine | hsa05170 | Human immunodeficiency virus 1 infection | 2.67E-05 | 16 | P31751, P04049, P0DP23, P01375, P17252, O00463, Q14643, P51617, P25963, O60603, Q13315, O95067, P10415, Q13619, Q93034, Q9Y6Q5 | AKT2, RAF1, CALM1, TNF, PRKCA, TRAF5, ITPR1, IRAK1, NFKBIA, TLR2, ATM, CCNB2, BCL2, CUL4A, CUL5, AP1M2 | More | | Alcaftadine | hsa05200 | Pathways in cancer | 1.81E-03 | 19 | Q13751, P42338, P08238, P19174, P43246, P84022, Q13485, Q13547, P30281, P49767, P31751, P43657, P63218, P50151, Q14344, Q7LDG7, O75293, P0DP23, P14784 | LAMB3, PIK3CB, HSP90AB1, PLCG1, MSH2, SMAD3, SMAD4, HDAC1, CCND3, VEGFC, AKT2, P2RY5, GNG5, GNG10, GNA13, RASGRP2, GADD45B, CALM1, IL2RB | More | | Alcaftadine | hsa05202 | Transcriptional misregulation in cancer | 7.38E-06 | 20 | Q12778, Q15532, Q13315, P17844, P14780, P27930, P14923, Q16548, Q13489, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | FOXO1, SS18, ATM, DDX5, MMP9, IL1R2, JUP, BCL2A1, BIRC3, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | | Alcaftadine | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Alcaftadine | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Alcaftadine | hsa05205 | Proteoglycans in cancer | 1.09E-02 | 6 | P04049, P14780, P01375, P23588, Q13635, P22694 | RAF1, MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Alcaftadine | hsa05206 | MicroRNAs in cancer | 3.15E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa05210 | Colorectal cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa05211 | Renal cell carcinoma | 1.29E-03 | 2 | P31751, P04049 | AKT2, RAF1 | More | | Alcaftadine | hsa05212 | Pancreatic cancer | 2.09E-03 | 6 | P42338, P31751, P04049, P84022, Q13485, O75293 | PIK3CB, AKT2, RAF1, SMAD3, SMAD4, GADD45B | More | | Alcaftadine | hsa05213 | Endometrial cancer | 8.16E-04 | 2 | P31751, P04049 | AKT2, RAF1 | More | | Alcaftadine | hsa05214 | Glioma | 8.46E-06 | 3 | P0DP23, P04049, P31751 | CALM1, RAF1, AKT2 | More | | Alcaftadine | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | | Alcaftadine | hsa05217 | Basal cell carcinoma | 3.50E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | Alcaftadine | hsa05218 | Melanoma | 4.47E-04 | 2 | P31751, P04049 | AKT2, RAF1 | More | | Alcaftadine | hsa05219 | Bladder cancer | 5.65E-03 | 3 | P14780, P04637, P04049 | MMP9, TP53, RAF1 | More | | Alcaftadine | hsa05220 | Chronic myeloid leukemia | 4.90E-04 | 7 | Q13547, Q13485, P84022, P31751, P42338, P04049, O75293 | HDAC1, SMAD4, SMAD3, AKT2, PIK3CB, RAF1, GADD45B | More | | Alcaftadine | hsa05221 | Acute myeloid leukemia | 8.16E-04 | 2 | P31751, P04049 | AKT2, RAF1 | More | | Alcaftadine | hsa05222 | Small cell lung cancer | 5.10E-03 | 7 | P31751, Q13489, P10415, P25963, Q13077, O00463, P24522 | AKT2, BIRC3, BCL2, NFKBIA, TRAF1, TRAF5, GADD45A | More | | Alcaftadine | hsa05223 | Non-small cell lung cancer | 3.89E-05 | 5 | P31751, P10826, P04049, Q9HC35, O75293 | AKT2, RARB, RAF1, EML4, GADD45B | More | | Alcaftadine | hsa05224 | Breast cancer | 1.24E-02 | 5 | P04049, P49841, Q92837, P04637, P24522 | RAF1, GSK3B, FRAT1, TP53, GADD45A | More | | Alcaftadine | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa05226 | Gastric cancer | 6.88E-05 | 4 | P04049, P31751, P04628, P10826 | RAF1, AKT2, WNT1, RARB | More | | Alcaftadine | hsa05230 | Central carbon metabolism in cancer | 1.12E-03 | 2 | P04049, P31751 | RAF1, AKT2 | More | | Alcaftadine | hsa05231 | Choline metabolism in cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | | Alcaftadine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 3.84E-06 | 12 | O95267, P07766, P20963, P09693, P06239, P04049, P23458, O60603, Q04759, Q16539, Q9HC35, P01730 | RASGRP1, CD3E, CD247, CD3G, LCK, RAF1, JAK1, TLR2, PRKCQ, MAPK14, EML4, CD4 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.852 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.716 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P52732 | KIF11 | Kinesin-like protein KIF11 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.724 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.835 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.744 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P52732 | KIF11 | Kinesin-like protein KIF11 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.721 | P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | 1 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.757 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O60603 | TLR2 | Toll-like receptor 2 | 0.842 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O60603 | TLR2 | Toll-like receptor 2 | 0.73 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 1 | P52732 | KIF11 | Kinesin-like protein KIF11 | Q9HC35 | EML4 | Echinoderm microtubule-associated protein-like 4 | 0.794 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.707 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P52732 | KIF11 | Kinesin-like protein KIF11 | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.719 |
| Alcaftadine | hsa05310 | Asthma | 3.88E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Alcaftadine | hsa05321 | Inflammatory bowel disease | 2.87E-05 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, P01584 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL1B | More | | Alcaftadine | hsa05322 | Systemic lupus erythematosus | 2.09E-04 | 12 | P08246, P08311, P09871, P01375, P10747, P13765, Q6FI13, Q93077, P62807, O60814, P68431, P05455 | ELA2, CTSG, C1S, TNF, CD28, HLA-DOB, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, SSB | More | | Alcaftadine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Alcaftadine | hsa05332 | Graft-versus-host disease | 2.84E-06 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | | Alcaftadine | hsa05340 | Primary immunodeficiency | 1.31E-04 | 5 | P01730, P01732, P11912, P07766, P06239 | CD4, CD8A, CD79A, CD3E, LCK | More | | Alcaftadine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | Alcaftadine | hsa05415 | Diabetic cardiomyopathy | 4.54E-04 | 8 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B, GAPDH | More | | Alcaftadine | hsa05418 | Fluid shear stress and atherosclerosis | 3.80E-04 | 9 | Q16539, P31751, P10599, P14780, P01375, P04637, P14778, P27930, P0DP23 | MAPK14, AKT2, TXN, MMP9, TNF, TP53, IL1R1, IL1R2, CALM1 | More | | |